event header image
https://flaia-cms-assets.s3.amazonaws.com/Esperante_Ventures_7b32bfabca.png

Esperante Ventures

Esperante Ventures: Bringing Innovation to Life Science Companies

Esperante Ventures is a corporate venture capital company affiliated with a privately-owned global life science group. With its headquarters in Siriusdreef Hoofddorp, North Holland 2132, NL, the company specializes in Venture Capital and Private Equity Principals. The leadership at Esperante Ventures boasts extensive experience in the operational management of life science companies. Their expertise lies in the development, manufacturing, and marketing of prescription pharmaceuticals and in vitro clinical diagnostic tests on a worldwide basis.

Since its establishment in 2004, Esperante Ventures has completed 24 pharmaceutical and diagnostic company investments across the US, UK, continental Europe, and Israel. Out of these investments, three exits have been delivered to date: Thiakis (UK) to Wyeth/Pfizer (US), Pinnacle Biologics (US) to Concordia (Canada), and Haemostatix (UK) to Ergomed (UK). Additionally, four portfolio companies are currently publicly listed in the US, Canada, and UK.

The therapeutics portfolio companies of Esperante Ventures are mainly in Phase 2 or 3 clinical development, and two diagnostics companies are in the European commercial launch phase. The company actively seeks to make initial investments of up to EUR 2,000,000 each in syndication with other investors. Their primary aim is to generate exit through sale or other liquidity outcomes within a period of three years.

Esperante Ventures has built a reputation for identifying and nurturing promising life science companies, helping them bring innovative products to market. By partnering with these companies, Esperante Ventures is playing a crucial role in the growth and development of the global life science industry.

For more information about Esperante Ventures, please visit their website at http://www.esperante.com.

Associated Speakers